ELF3-2 Antibody

What is ELF3 and what are its known functions in cellular processes?

ELF3 (E74 like ETS transcription factor 3) is a human protein that functions as a transcription factor belonging to the ETS family. It is also known by several aliases including ERT, ESX, EPR-1, ESE-1, and ETS-related transcription factor Elf-3. Structurally, ELF3 is a protein with a molecular weight of approximately 41.5 kilodaltons . ELF3 plays crucial roles in epithelial cell differentiation, inflammatory responses, and has been implicated in various cancer types where it can function as either an oncogene or tumor suppressor depending on the cellular context. The protein contains an ETS DNA-binding domain that recognizes specific genomic sequences, allowing it to regulate the transcription of target genes involved in cellular proliferation, differentiation, and tissue-specific functions.

How does ELF3-2 antibody differ from other ELF3 antibody variants?

ELF3-2 antibodies are designed to recognize specific epitopes or regions of the ELF3 protein that may be distinct from those targeted by other ELF3 antibody variants. While the search results don't explicitly detail the differences between ELF3-2 and other variants, antibodies against the same target protein often differ in their epitope recognition, clonality, host species, and affinity characteristics . ELF3-2 antibodies may target a specific isoform, post-translational modification, or a unique region of the ELF3 protein that distinguishes it from other variants. When selecting between different ELF3 antibody variants, researchers should consider the specific experimental requirements and whether epitope accessibility might be affected by protein conformation, interaction partners, or post-translational modifications in their experimental system.

What are the primary research applications for ELF3-2 antibodies?

ELF3-2 antibodies can be utilized across numerous research applications, with the most common being:

• Western Blot (WB): For detecting and quantifying ELF3 protein in cell or tissue lysates

• Immunohistochemistry (IHC): For visualizing ELF3 expression patterns in tissue sections

• Immunofluorescence (IF/ICC): For subcellular localization studies

• Chromatin Immunoprecipitation (ChIP): For identifying DNA binding sites and transcriptional targets

• Immunoprecipitation (IP): For studying protein-protein interactions

• ELISA: For quantitative detection in solution

Different antibodies may be validated for specific applications, so researchers should select antibodies that have been verified for their intended experimental methods. For example, some ELF3 antibodies are specifically validated for applications such as ChIP-seq, which requires high specificity and low background binding .

What species reactivity should be considered when selecting an ELF3-2 antibody?

When selecting an ELF3-2 antibody, species reactivity is a critical consideration that depends on your experimental model system. Based on the available antibody products, ELF3 antibodies demonstrate various patterns of cross-reactivity:

Many antibodies are designed to target human ELF3, with cross-reactivity to mouse and rat orthologs in some cases . Some antibodies may specifically recognize only one species due to sequence variations in the target epitope. When working with non-human models, it's essential to verify species cross-reactivity experimentally, even if the manufacturer claims reactivity, as sequence homology does not always translate to equivalent antibody binding affinity.

How should clonality be considered when selecting ELF3-2 antibodies?

The choice between monoclonal and polyclonal ELF3-2 antibodies depends on experimental requirements:

Monoclonal ELF3-2 Antibodies:

• Recognize a single epitope on the ELF3 protein

• Offer high specificity and consistency between batches

• Available in various clones (e.g., 1D8, F8J2G, F6Z8R, OTI6G6)

• May have limited ability to recognize denatured protein if the epitope is conformational

• Ideal for applications requiring high reproducibility and minimal background

Polyclonal ELF3-2 Antibodies:

• Recognize multiple epitopes on the ELF3 protein

• Provide enhanced sensitivity, especially useful for low-abundance targets

• More tolerant of minor protein denaturation or modifications

• May show batch-to-batch variation

• Better for antigen capture in immunoprecipitation

For applications like Western blotting where protein is denatured, polyclonal antibodies may provide higher sensitivity, while monoclonal antibodies are often preferred for immunohistochemistry where specificity is paramount to avoid cross-reactivity with similar proteins.

What are the optimal conditions for using ELF3-2 antibodies in Western blot applications?

Optimizing Western blot protocols for ELF3-2 antibody detection requires attention to several parameters:

Sample Preparation:

• Complete cell lysis using RIPA or NP-40 buffer supplemented with protease inhibitors

• Include phosphatase inhibitors if phosphorylated forms are of interest

• Denature samples at 95°C for 5 minutes in reducing sample buffer

Gel Electrophoresis and Transfer:

• Use 10-12% polyacrylamide gels for optimal resolution around the 41.5 kDa range of ELF3

• Transfer to PVDF membranes (rather than nitrocellulose) for stronger protein binding

• Use wet transfer for 60-90 minutes at 100V or overnight at 30V

Antibody Incubation:

• Blocking: 5% non-fat dry milk in TBST (for most applications) or 3-5% BSA if phospho-specific detection is needed

• Primary antibody dilution: Typically 1:1000-1:2000, but verify manufacturer's recommendations

• Incubation: Overnight at 4°C with gentle agitation

• Secondary antibody: Anti-rabbit or anti-mouse HRP conjugates at 1:5000-1:10000 for 1 hour at room temperature

Detection:

• Enhanced chemiluminescence (ECL) substrates with appropriate sensitivity for your target abundance

• Exposure time optimization to prevent signal saturation

When troubleshooting weak signals, consider increasing antibody concentration, extending incubation time, using more sensitive detection reagents, or enriching your target protein through immunoprecipitation before Western blotting .

How can I optimize immunohistochemistry protocols using ELF3-2 antibodies?

Successful immunohistochemistry (IHC) with ELF3-2 antibodies requires careful attention to several critical steps:

Tissue Preparation:

• Fixation: 10% neutral buffered formalin for 24-48 hours is standard

• Embedding and sectioning: 4-6 μm sections for optimal antibody penetration

Antigen Retrieval (critical for FFPE tissues):

• Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Pressure cooker or microwave methods (20 minutes) generally provide more consistent results than water bath methods

Blocking and Antibody Incubation:

• Endogenous peroxidase blocking: 3% hydrogen peroxide for 10 minutes

• Protein blocking: 5-10% normal serum from the same species as the secondary antibody

• Primary antibody dilution: Typically 1:100-1:500 (optimize through titration)

• Incubation: 1 hour at room temperature or overnight at 4°C in a humidified chamber

Detection System:

• Use of polymer-based detection systems generally provides better sensitivity than avidin-biotin complex methods

• DAB (3,3'-diaminobenzidine) substrate for chromogenic detection

• Counterstain with hematoxylin for cellular context

Several ELF3 antibodies have been specifically validated for IHC applications in human and rodent tissues, with optimal dilutions varying by specific antibody clone . Always include positive control tissues known to express ELF3 and negative controls (omitting primary antibody) to validate staining specificity.

How can I validate the specificity of my ELF3-2 antibody?

Thorough validation of ELF3-2 antibody specificity is crucial for generating reliable research data. Implement these complementary validation strategies:

Positive and Negative Controls:

• Positive controls: Cell lines with known high ELF3 expression (e.g., certain epithelial cancer cell lines)

• Negative controls: Cell lines with minimal ELF3 expression

• Genetic controls: ELF3 knockdown/knockout samples via siRNA, shRNA, or CRISPR-Cas9

Multiple Detection Methods:

• Compare results across different applications (WB, IHC, IF)

• Use multiple antibodies targeting different ELF3 epitopes

• Correlate protein detection with mRNA expression data

Blocking Peptide Competition:

• Pre-incubate antibody with excess immunizing peptide

• Specific signals should be substantially reduced or eliminated

Mass Spectrometry Validation:

• Immunoprecipitate ELF3 and confirm identity by mass spectrometry

• Identifies potential cross-reacting proteins

Recombinant Protein Controls:

• Test against purified recombinant ELF3 protein

• Include related family members (other ETS factors) to assess cross-reactivity

Maintaining detailed validation records for each antibody lot is essential, as manufacturing variations can affect specificity and sensitivity .

What are the critical considerations for using ELF3-2 antibodies in ChIP experiments?

Chromatin immunoprecipitation (ChIP) with ELF3-2 antibodies requires special considerations:

Antibody Selection:

• Choose antibodies specifically validated for ChIP applications

• ChIP-grade antibodies typically recognize native (non-denatured) epitopes

• Several ELF3 antibodies have been validated for ChIP and ChIP-seq applications, including the F8J2G rabbit monoclonal antibody

Crosslinking Optimization:

• Standard: 1% formaldehyde for 10 minutes at room temperature

• May require optimization as excessive crosslinking can mask epitopes

• Quench with 125 mM glycine

Chromatin Fragmentation:

• Target fragment size of 200-500 bp for standard ChIP, 100-300 bp for ChIP-seq

• Optimize sonication conditions for each cell type

• Verify fragmentation by agarose gel electrophoresis

Immunoprecipitation Conditions:

• Pre-clear chromatin with protein A/G beads to reduce background

• Use 2-5 μg antibody per ChIP reaction (optimize by titration)

• Include appropriate controls:

  • Input chromatin (pre-immunoprecipitation sample)

  • IgG control (same species as ELF3 antibody)

  • Positive control antibody (e.g., histone H3)

Data Analysis:

• For ChIP-qPCR: Include both positive targets (known ELF3 binding sites) and negative regions

• For ChIP-seq: Use appropriate peak calling algorithms considering the binding characteristics of ETS family transcription factors

Successful ChIP experiments with ELF3-2 antibodies often require more extensive optimization than other applications due to the complex nature of protein-DNA interactions and the need for high specificity .

How does post-translational modification of ELF3 affect antibody recognition?

Post-translational modifications (PTMs) of ELF3 can significantly impact antibody recognition, introducing an important variable in experimental interpretation:

Common ELF3 Modifications:

• Phosphorylation: Multiple serine/threonine and tyrosine residues

• SUMOylation: Regulates stability and transcriptional activity

• Ubiquitination: Controls protein degradation

• Acetylation: Affects DNA binding ability

Modification Effects on Antibody Binding:

• Epitope masking: PTMs may directly block antibody access to its epitope

• Conformational changes: PTMs can alter protein folding, indirectly affecting epitope accessibility

• Signal enhancement/reduction: Depending on the antibody's specificity, PTMs may increase or decrease binding affinity

Strategies for Addressing PTM Variability:

• Use multiple antibodies targeting different regions of ELF3

• Consider phosphatase treatment of samples to eliminate phosphorylation-dependent variations

• Select modification-insensitive antibodies for total ELF3 detection

• Use modification-specific antibodies when studying particular modified forms

When interpreting variable results between experiments or cell types, consider whether differential post-translational modification states might explain observed differences in antibody reactivity. This is particularly important in studying ELF3 in cancer contexts, where abnormal PTM patterns often occur .

What controls should be included when using ELF3-2 antibodies?

Implementing appropriate controls is essential for generating reliable and interpretable results with ELF3-2 antibodies:

Essential Experimental Controls:

Application-Specific Controls:

• For WB: Molecular weight markers to confirm band size corresponds to ELF3 (41.5 kDa)

• For IHC/IF: Secondary-only controls to evaluate background staining

• For ChIP: Input sample (pre-IP chromatin) and IgG control IP

• For IP: Pre-immune serum or irrelevant antibody IP

Consistent implementation of these controls across experiments facilitates reproducibility and enables accurate comparison of results across different experimental conditions or between different laboratories .

How should I interpret inconsistent results between different ELF3-2 antibodies?

Discrepancies between different ELF3-2 antibodies are not uncommon and require systematic investigation:

Common Causes of Inconsistency:

• Epitope differences: Antibodies recognizing different regions of ELF3 may give different results, especially if:

  • The protein is alternatively spliced

  • Some epitopes are masked in protein complexes

  • Post-translational modifications affect epitope accessibility

• Technical factors:

  • Application-specific performance (an antibody optimal for WB may perform poorly in IHC)

  • Batch-to-batch variation, especially in polyclonal antibodies

  • Differing sensitivities between antibodies

• Biological variables:

  • Cell-type specific ELF3 isoform expression

  • Context-dependent protein interactions

  • Differential post-translational modifications

Recommended Resolution Approach:

• Verify antibody validation data from manufacturers

• Compare epitope locations of different antibodies

• Use orthogonal methods to confirm results (e.g., mRNA analysis, mass spectrometry)

• Implement genetic approaches (siRNA, CRISPR) to validate specificity

• Consider using antibody cocktails (multiple antibodies) for more comprehensive detection

When publishing results, transparently report which antibody clone or catalog number was used, including dilution and incubation conditions, to enable reproducibility by other researchers .

What are the optimal storage and handling conditions for ELF3-2 antibodies?

Proper storage and handling of ELF3-2 antibodies is critical for maintaining their performance over time:

Long-term Storage:

• Store antibodies at -20°C in small aliquots to minimize freeze-thaw cycles

• For conjugated antibodies (e.g., fluorophore-labeled), protect from light during storage

• Some antibody formulations may recommend -80°C storage for extended shelf-life

Working Solution Handling:

• Keep antibodies on ice when in use during experiments

• For diluted working solutions, store at 4°C and use within 1-2 weeks

• Add preservatives (e.g., 0.02% sodium azide) to diluted antibodies stored at 4°C

Freeze-Thaw Considerations:

• Limit freeze-thaw cycles to 5 or fewer

• Create small single-use aliquots upon first thaw

• Allow antibodies to thaw completely at 4°C before use

• Avoid vortexing antibodies; mix by gentle inversion or flicking

Antibody Dilution:

• Use high-quality, filtered buffers for dilution

• Include carrier proteins (0.1-0.5% BSA) in dilution buffers to prevent antibody adsorption to tubes

• For IHC/IF applications, consider commercial antibody diluents with background-reducing components

Following these guidelines will help maintain antibody performance and extend usable shelf-life, ensuring consistent results across experiments. Always refer to manufacturer-specific recommendations, as optimal conditions may vary between different antibody formulations and clones .

How can ELF3-2 antibodies be utilized in multiplexed immunofluorescence studies?

Multiplexed immunofluorescence (mIF) with ELF3-2 antibodies enables simultaneous visualization of multiple markers in the same tissue section, providing valuable spatial context for understanding ELF3 biology:

Panel Design Considerations:

• Select ELF3-2 antibodies raised in different host species than other target antibodies

• Alternatively, use directly conjugated primary antibodies to avoid species cross-reactivity

• Ensure spectral separation between fluorophores to minimize bleed-through

• Consider tyramide signal amplification (TSA) for detecting low-abundance targets alongside ELF3

Sequential Staining Protocol:

• Perform antigen retrieval optimized for all targets

• Block with sera from all secondary antibody host species

• Apply first primary antibody (e.g., ELF3-2)

• Detect with fluorophore-conjugated secondary or TSA system

• Perform antibody stripping/inactivation (if using same species antibodies)

• Repeat steps 3-5 for each additional marker

• Counterstain nuclei (DAPI) and apply anti-fade mounting medium

Validation Requirements:

• Single-color controls to assess antibody specificity and optimize exposure settings

• Fluorophore-minus-one (FMO) controls to evaluate bleed-through

• Replicate staining with alternative antibody order to confirm epitope stability through multiple rounds

Analysis Approaches:

• Use spectral unmixing software for closely overlapping fluorophores

• Implement automated image analysis for quantitative assessment of co-localization

• Consider cell segmentation algorithms for single-cell analysis of ELF3 expression in heterogeneous tissues

This approach is particularly valuable for studying ELF3 in cancer contexts, where correlation with cell type markers, proliferation status, and other transcription factors can provide insights into its functional role in tumor progression .

What considerations are important when using ELF3-2 antibodies for studying protein-protein interactions?

Investigating ELF3 protein interactions requires careful selection of methods and conditions:

Co-Immunoprecipitation (Co-IP):

• Select antibodies validated for immunoprecipitation applications

• Use gentle lysis buffers (e.g., NP-40) to preserve protein complexes

• Consider crosslinking approaches for transient interactions

• Include RNase treatment controls to distinguish RNA-mediated from direct protein interactions

• Several ELF3 antibodies have been specifically validated for immunoprecipitation applications, including the F6Z8R rabbit monoclonal antibody

Proximity Ligation Assay (PLA):

• Requires two primary antibodies from different species

• Provides spatial resolution of interactions in situ

• Optimize antibody concentrations to minimize background

• Include appropriate negative controls (known non-interacting proteins)

FRET/BiFC Approaches:

• Requires genetic manipulation to tag ELF3 and potential partners

• Consider tag placement to avoid disrupting interaction interfaces

• Validate that tagged ELF3 retains normal localization and function

Mass Spectrometry-Based Approaches:

• Use antibodies conjugated to beads for efficient pulldown

• Consider both native IP and crosslinked IP to capture different interaction types

• Include stringent controls (IgG, competing peptide) to filter out non-specific interactors

When interpreting results, consider that ELF3 interactions may be highly context-dependent, varying with cell type, stimulation conditions, and post-translational modification status. Validation across multiple methods and cell types is recommended for high-confidence interaction partners .

How can I troubleshoot weak or non-specific signals when using ELF3-2 antibodies?

When encountering signal problems with ELF3-2 antibodies, a systematic troubleshooting approach can identify and resolve the underlying issues:

Weak or Absent Signal:

High Background or Non-specific Signals:

Multiple Bands in Western Blot:

For application-specific troubleshooting, consult detailed protocols and consider reaching out to the antibody manufacturer's technical support for guidance tailored to your specific experimental system .